Bone Biologics Corporation is a developer of orthobiologic products for spine fusion markets. It is focusing development efforts for its bone graft substitute product on bone regeneration in spinal fusion procedures, while additionally having rights to trauma and osteoporosis applications. It is a medical device company that is focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with demineralized bone matrix (DBM), is an osteopromotive recombinant protein that provides target specific control over bone regeneration. Its platform technology is its NELL-1, a proprietary skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The DBM Demineralized Bone Putty provided as part of the convenience kit with NELL-1/DBM is a Class II device. DBM Putty is a matrix composed of processed human cortical bone.
Código da empresaBBLGW
Nome da EmpresaBone Biologics Corp
Data de listagemNov 27, 2015
CEOMr. Jeffrey Frelick
Número de funcionários- -
Tipo de títulosCompany Warrant
Fim do ano fiscal- -
Endereço2 Burlington Woods Dr Ste 100
CidadeBURLINGTON
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01803-4551
Telefone17815524452
Sitehttps://www.bonebiologics.com/
Código da empresaBBLGW
Data de listagemNov 27, 2015
CEOMr. Jeffrey Frelick
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.

Sem dados